Details of the Drug

General Information of Drug (ID: DM7EVLC)

Drug Name
Bendroflumethiazide
Synonyms
Aprinox; BHFT; Bendrofluazide; Bendroflumethazide; Bendroflumethiazidum; Bendroflumetiazida; Bendroflumetiazide; Bendrofumethiazide; Bentride; Benuron; Benzhydroflumethiazide; Benzydroflumethiazide; Benzylhydroflumethiazide; Benzylrodiuran; Berkozide; Bristuric; Bristuron; Centyl; Corzide; Flumersil; Flumesil; Intolex; Livesan; Naigaril; Nateretin; Naturetin; Naturine; Niagaril; Nikion; Orsile; Pluryl; Pluryle; Plusuril; Poliuron; Rauzide; Repicin; Salural; Salures; Sinesalin; Sodiuretic; Thiazidico; Urlea; Bendroflumethiazide [USP]; Bendroflumetiazide [DCIT]; Rautrax N; Relan beta; BL H368; FT 8; FT 81; Be 724-A; Bendroflumethiazidum [INN-Latin]; Bendroflumetiazida [INN-Spanish]; Benzy-rodiuran; NATURETIN-10; NATURETIN-5; Naturetin (TN); Neo-naclex; Neo-rontyl; Naturetin-2.5; Bendroflumethiazide (JAN/USP/INN); (+-)-3-Benzyl-3,4-dihydro-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-3-(phenylmethyl)-6-(trifluoromethyl)-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-benzyl-3,4-dihydro-6-(trifluoromethyl)-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-benzyl-3,4-dihydro-6-(trifluoromethyl)-,1,1-dioxide; 3,4-Dihydro-3-(phenylmethyl)-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide1,1-dioxide; 3-(phenylmethyl)-6-(trifluoromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Benzyl-3,4-dihydro-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Benzyl-6-(trifluoromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Benzyl-6-trifluoromethyl-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazine, 1,1-dioxide; 3-Benzyl-6-trifluoromethyl-7-sulfamoyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-Trifluoromethyl-3-benzyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine, 1,1-dioxide; 6-trifluoromethyl-3-benzyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide
Indication
Disease Entry ICD 11 Status REF
High blood pressure BA00 Approved [1], [2]
Therapeutic Class
Antihypertensive Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 421.4
Topological Polar Surface Area (xlogp) 1.2
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 10
ADMET Property
Absorption
The drug is rapidly absorbed after oral administration [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [4]
Bioavailability
90% of drug becomes completely available to its intended biological destination(s) [5]
Elimination
21% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 8.5 hours [6]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.79019 micromolar/kg/day [7]
Water Solubility
The ability of drug to dissolve in water is measured as 0.108 mg/mL [4]
Chemical Identifiers
Formula
C15H14F3N3O4S2
IUPAC Name
3-benzyl-1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide
Canonical SMILES
C1=CC=C(C=C1)CC2NC3=C(C=C(C(=C3)C(F)(F)F)S(=O)(=O)N)S(=O)(=O)N2
InChI
InChI=1S/C15H14F3N3O4S2/c16-15(17,18)10-7-11-13(8-12(10)26(19,22)23)27(24,25)21-14(20-11)6-9-4-2-1-3-5-9/h1-5,7-8,14,20-21H,6H2,(H2,19,22,23)
InChIKey
HDWIHXWEUNVBIY-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2315
ChEBI ID
CHEBI:3013
CAS Number
73-48-3
DrugBank ID
DB00436
TTD ID
D02PAH
VARIDT ID
DR01028

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Solute carrier family 12 member 1 (SLC12A1) TTS087L S12A1_HUMAN Blocker [8]
Solute carrier family 12 member 3 (SLC12A3) TTP362L S12A3_HUMAN Blocker [8], [9]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Bendroflumethiazide
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Ethacrynic acid DM60QMR Moderate Increased risk of fluid/electrolyte loss by the combination of Bendroflumethiazide and Ethacrynic acid. Essential hypertension [BA00] [18]
Nadolol DMW6GVL Moderate Increased risk of hyperglycemia by the combination of Bendroflumethiazide and Nadolol. Essential hypertension [BA00] [19]
Coadministration of a Drug Treating the Disease Different from Bendroflumethiazide (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Scopolamine DMOM8AL Minor Altered absorption of Bendroflumethiazide due to GI dynamics variation caused by Scopolamine. Addictive disorder [6C50-6C5Z] [20]
Dronedarone DMA8FS5 Major Increased risk of ventricular arrhythmias by the combination of Bendroflumethiazide and Dronedarone. Angina pectoris [BA40] [21]
Linezolid DMGFPU2 Moderate Additive hypotensive effects by the combination of Bendroflumethiazide and Linezolid. Bacterial infection [1A00-1C4Z] [22]
Rabeprazole DMMZXIW Moderate Increased risk of hypomagnesemia by the combination of Bendroflumethiazide and Rabeprazole. Bacterial infection [1A00-1C4Z] [23]
Cariprazine DMJYDVK Moderate Additive hypotensive effects by the combination of Bendroflumethiazide and Cariprazine. Bipolar disorder [6A60] [24]
Sotalol DML60TN Moderate Increased risk of hyperglycemia by the combination of Bendroflumethiazide and Sotalol. Cardiac arrhythmia [BC9Z] [19]
Ketoprofen DMRKXPT Moderate Antagonize the effect of Bendroflumethiazide when combined with Ketoprofen. Chronic pain [MG30] [25]
Levomilnacipran DMV26S8 Moderate Increased risk of hyponatremia by the combination of Bendroflumethiazide and Levomilnacipran. Chronic pain [MG30] [26]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Bendroflumethiazide and Olopatadine. Conjunctiva disorder [9A60] [27]
Fluoxetine DM3PD2C Moderate Increased risk of hyponatremia by the combination of Bendroflumethiazide and Fluoxetine. Depression [6A70-6A7Z] [26]
Vilazodone DM4LECQ Moderate Increased risk of hyponatremia by the combination of Bendroflumethiazide and Vilazodone. Depression [6A70-6A7Z] [26]
Paroxetine DM5PVQE Moderate Increased risk of hyponatremia by the combination of Bendroflumethiazide and Paroxetine. Depression [6A70-6A7Z] [26]
Selegiline DM6034S Moderate Additive hypotensive effects by the combination of Bendroflumethiazide and Selegiline. Depression [6A70-6A7Z] [22]
Vortioxetine DM6F1PU Moderate Increased risk of hyponatremia by the combination of Bendroflumethiazide and Vortioxetine. Depression [6A70-6A7Z] [26]
Duloxetine DM9BI7M Moderate Increased risk of hyponatremia by the combination of Bendroflumethiazide and Duloxetine. Depression [6A70-6A7Z] [26]
Isocarboxazid DMAF1NB Moderate Additive hypotensive effects by the combination of Bendroflumethiazide and Isocarboxazid. Depression [6A70-6A7Z] [22]
Milnacipran DMBFE74 Moderate Increased risk of hyponatremia by the combination of Bendroflumethiazide and Milnacipran. Depression [6A70-6A7Z] [26]
Desvenlafaxine DMHD4PE Moderate Increased risk of hyponatremia by the combination of Bendroflumethiazide and Desvenlafaxine. Depression [6A70-6A7Z] [26]
OPC-34712 DMHG57U Moderate Additive hypotensive effects by the combination of Bendroflumethiazide and OPC-34712. Depression [6A70-6A7Z] [24]
Phenelzine DMHIDUE Moderate Additive hypotensive effects by the combination of Bendroflumethiazide and Phenelzine. Depression [6A70-6A7Z] [22]
Mepenzolate DM8YU2F Minor Altered absorption of Bendroflumethiazide due to GI dynamics variation caused by Mepenzolate. Digestive system disease [DE2Z] [20]
Oxybutynine DMJPBAX Minor Altered absorption of Bendroflumethiazide due to GI dynamics variation caused by Oxybutynine. Discovery agent [N.A.] [20]
Carbamazepine DMZOLBI Moderate Increased risk of hyponatremia by the combination of Bendroflumethiazide and Carbamazepine. Epilepsy/seizure [8A61-8A6Z] [28]
Eslicarbazepine DMZREFQ Moderate Increased risk of hyponatremia by the combination of Bendroflumethiazide and Eslicarbazepine. Epilepsy/seizure [8A61-8A6Z] [29]
Mefenamic acid DMK7HFI Moderate Antagonize the effect of Bendroflumethiazide when combined with Mefenamic acid. Female pelvic pain [GA34] [25]
Solifenacin DMG592Q Minor Altered absorption of Bendroflumethiazide due to GI dynamics variation caused by Solifenacin. Functional bladder disorder [GC50] [20]
Tolterodine DMSHPW8 Minor Altered absorption of Bendroflumethiazide due to GI dynamics variation caused by Tolterodine. Functional bladder disorder [GC50] [20]
Darifenacin DMWXLYZ Minor Altered absorption of Bendroflumethiazide due to GI dynamics variation caused by Darifenacin. Functional bladder disorder [GC50] [20]
Propantheline DM2EN6G Minor Altered absorption of Bendroflumethiazide due to GI dynamics variation caused by Propantheline. Gastric ulcer [DA60] [20]
Dexlansoprazole DM1DBV5 Moderate Increased risk of hypomagnesemia by the combination of Bendroflumethiazide and Dexlansoprazole. Gastro-oesophageal reflux disease [DA22] [23]
Cisapride DMY7PED Major Increased risk of ventricular arrhythmias by the combination of Bendroflumethiazide and Cisapride. Gastro-oesophageal reflux disease [DA22] [30]
Carteolol DMFMDOB Moderate Increased risk of ventricular arrhythmias by the combination of Bendroflumethiazide and Carteolol. Glaucoma [9C61] [19]
Metipranolol DMJMVKI Moderate Increased risk of hypertriglyceridemia by the combination of Bendroflumethiazide and Metipranolol. Glaucoma [9C61] [19]
Levobunolol DMTNFCQ Moderate Increased risk of ventricular arrhythmias by the combination of Bendroflumethiazide and Levobunolol. Glaucoma [9C61] [19]
Carvedilol DMHTEAO Moderate Increased risk of ventricular arrhythmias by the combination of Bendroflumethiazide and Carvedilol. Heart failure [BD10-BD1Z] [19]
Furosemide DMMQ8ZG Moderate Increased risk of fluid/electrolyte loss by the combination of Bendroflumethiazide and Furosemide. Heart failure [BD10-BD1Z] [18]
Bumetanide DMRV7H0 Moderate Increased risk of fluid/electrolyte loss by the combination of Bendroflumethiazide and Bumetanide. Heart failure [BD10-BD1Z] [18]
Acebutolol DM0TI4U Moderate Increased risk of hyperglycemia by the combination of Bendroflumethiazide and Acebutolol. Hypertension [BA00-BA04] [19]
Moexipril DM26E4B Moderate Additive hypotensive effects by the combination of Bendroflumethiazide and Moexipril. Hypertension [BA00-BA04] [31]
Bisoprolol DM3UZ95 Moderate Increased risk of hyperglycemia by the combination of Bendroflumethiazide and Bisoprolol. Hypertension [BA00-BA04] [19]
Captopril DM458UM Moderate Additive hypotensive effects by the combination of Bendroflumethiazide and Captopril. Hypertension [BA00-BA04] [31]
Trandolapril DM4L6EU Moderate Additive hypotensive effects by the combination of Bendroflumethiazide and Trandolapril. Hypertension [BA00-BA04] [31]
Nebivolol DM7F1PA Moderate Increased risk of hypertriglyceridemia by the combination of Bendroflumethiazide and Nebivolol. Hypertension [BA00-BA04] [19]
Fosinopril DM9NJ52 Moderate Additive hypotensive effects by the combination of Bendroflumethiazide and Fosinopril. Hypertension [BA00-BA04] [31]
Pindolol DMD2NV7 Moderate Increased risk of hyperglycemia by the combination of Bendroflumethiazide and Pindolol. Hypertension [BA00-BA04] [19]
Benazepril DMH1M9B Moderate Additive hypotensive effects by the combination of Bendroflumethiazide and Benazepril. Hypertension [BA00-BA04] [31]
Labetalol DMK8U72 Moderate Increased risk of hypertriglyceridemia by the combination of Bendroflumethiazide and Labetalol. Hypertension [BA00-BA04] [19]
Enalapril DMNFUZR Moderate Additive hypotensive effects by the combination of Bendroflumethiazide and Enalapril. Hypertension [BA00-BA04] [31]
Perindopril DMOPZDT Moderate Additive hypotensive effects by the combination of Bendroflumethiazide and Perindopril. Hypertension [BA00-BA04] [31]
Quinapril DMR8H31 Moderate Additive hypotensive effects by the combination of Bendroflumethiazide and Quinapril. Hypertension [BA00-BA04] [31]
Lisinopril DMUOK4C Moderate Additive hypotensive effects by the combination of Bendroflumethiazide and Lisinopril. Hypertension [BA00-BA04] [31]
Belladonna DM2RBWK Minor Altered absorption of Bendroflumethiazide due to GI dynamics variation caused by Belladonna. Infectious gastroenteritis/colitis [1A40] [20]
Meclofenamic acid DM05FXR Moderate Antagonize the effect of Bendroflumethiazide when combined with Meclofenamic acid. Inflammatory spondyloarthritis [FA92] [25]
ITI-007 DMUQ1DO Moderate Additive hypotensive effects by the combination of Bendroflumethiazide and ITI-007. Insomnia [7A00-7A0Z] [24]
Clidinium DMUMQZ0 Minor Altered absorption of Bendroflumethiazide due to GI dynamics variation caused by Clidinium. Irritable bowel syndrome [DD91] [20]
Dicyclomine DMZSDGX Minor Altered absorption of Bendroflumethiazide due to GI dynamics variation caused by Dicyclomine. Irritable bowel syndrome [DD91] [20]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Bendroflumethiazide and Porfimer Sodium. Lung cancer [2C25] [32]
Arsenic trioxide DM61TA4 Major Increased risk of ventricular arrhythmias by the combination of Bendroflumethiazide and Arsenic trioxide. Mature B-cell lymphoma [2A85] [33]
Propranolol DM79NTF Moderate Increased risk of hyperglycemia by the combination of Bendroflumethiazide and Propranolol. Migraine [8A80] [19]
Ozanimod DMT6AM2 Moderate Additive hypotensive effects by the combination of Bendroflumethiazide and Ozanimod. Multiple sclerosis [8A40] [22]
Methoxsalen DME8FZ9 Moderate Increased risk of photosensitivity reactions by the combination of Bendroflumethiazide and Methoxsalen. Mycosis fungoides [2B01] [34]
Droperidol DM0DXA8 Major Increased risk of ventricular arrhythmias by the combination of Bendroflumethiazide and Droperidol. Nausea/vomiting [MD90] [35]
Promethazine DM6I5GR Moderate Additive hypotensive effects by the combination of Bendroflumethiazide and Promethazine. Nausea/vomiting [MD90] [24]
Sibutramine DMFJTDI Moderate Increased risk of hyponatremia by the combination of Bendroflumethiazide and Sibutramine. Obesity [5B80-5B81] [26]
Levomethadyl Acetate DM06HG5 Major Increased risk of ventricular arrhythmias by the combination of Bendroflumethiazide and Levomethadyl Acetate. Opioid use disorder [6C43] [36]
Diclofenac DMPIHLS Moderate Antagonize the effect of Bendroflumethiazide when combined with Diclofenac. Osteoarthritis [FA00-FA05] [25]
Naproxen DMZ5RGV Moderate Antagonize the effect of Bendroflumethiazide when combined with Naproxen. Osteoarthritis [FA00-FA05] [25]
Etodolac DM6WJO9 Moderate Antagonize the effect of Bendroflumethiazide when combined with Etodolac. Pain [MG30-MG3Z] [25]
Diflunisal DM7EN8I Moderate Antagonize the effect of Bendroflumethiazide when combined with Diflunisal. Pain [MG30-MG3Z] [25]
Ibuprofen DM8VCBE Moderate Antagonize the effect of Bendroflumethiazide when combined with Ibuprofen. Pain [MG30-MG3Z] [25]
Nabumetone DMAT2XH Moderate Antagonize the effect of Bendroflumethiazide when combined with Nabumetone. Pain [MG30-MG3Z] [25]
Flavoxate DMKV4NL Minor Altered absorption of Bendroflumethiazide due to GI dynamics variation caused by Flavoxate. Pain [MG30-MG3Z] [20]
Piroxicam DMTK234 Moderate Antagonize the effect of Bendroflumethiazide when combined with Piroxicam. Pain [MG30-MG3Z] [25]
Safinamide DM0YWJC Moderate Additive hypotensive effects by the combination of Bendroflumethiazide and Safinamide. Parkinsonism [8A00] [22]
Rasagiline DM3WKQ4 Moderate Additive hypotensive effects by the combination of Bendroflumethiazide and Rasagiline. Parkinsonism [8A00] [22]
Biperiden DME78OA Minor Altered absorption of Bendroflumethiazide due to GI dynamics variation caused by Biperiden. Parkinsonism [8A00] [20]
Methylscopolamine DM5VWOB Minor Altered absorption of Bendroflumethiazide due to GI dynamics variation caused by Methylscopolamine. Peptic ulcer [DA61] [20]
Esomeprazole DM7BN0X Moderate Increased risk of hypomagnesemia by the combination of Bendroflumethiazide and Esomeprazole. Peptic ulcer [DA61] [23]
Ketorolac DMI4EL5 Moderate Antagonize the effect of Bendroflumethiazide when combined with Ketorolac. Postoperative inflammation [1A00-CA43] [25]
Verteporfin DMIY6DB Moderate Increased risk of photosensitivity reactions by the combination of Bendroflumethiazide and Verteporfin. Psoriasis [EA90] [37]
Fluphenazine DMIT8LX Moderate Increased risk of ventricular arrhythmias by the combination of Bendroflumethiazide and Fluphenazine. Psychotic disorder [6A20-6A25] [34]
Meloxicam DM2AR7L Moderate Antagonize the effect of Bendroflumethiazide when combined with Meloxicam. Rheumatoid arthritis [FA20] [25]
Sulindac DM2QHZU Moderate Antagonize the effect of Bendroflumethiazide when combined with Sulindac. Rheumatoid arthritis [FA20] [25]
Celecoxib DM6LOQU Moderate Antagonize the effect of Bendroflumethiazide when combined with Celecoxib. Rheumatoid arthritis [FA20] [25]
Oxaprozin DM9UB0P Moderate Antagonize the effect of Bendroflumethiazide when combined with Oxaprozin. Rheumatoid arthritis [FA20] [25]
Flurbiprofen DMGN4BY Moderate Antagonize the effect of Bendroflumethiazide when combined with Flurbiprofen. Rheumatoid arthritis [FA20] [25]
Fenoprofen DML5VQ0 Moderate Antagonize the effect of Bendroflumethiazide when combined with Fenoprofen. Rheumatoid arthritis [FA20] [25]
Tolmetin DMWUIJE Moderate Antagonize the effect of Bendroflumethiazide when combined with Tolmetin. Rheumatoid arthritis [FA20] [25]
Quetiapine DM1N62C Moderate Additive hypotensive effects by the combination of Bendroflumethiazide and Quetiapine. Schizophrenia [6A20] [24]
Mesoridazine DM2ZGAN Moderate Increased risk of ventricular arrhythmias by the combination of Bendroflumethiazide and Mesoridazine. Schizophrenia [6A20] [34]
Thioridazine DM35M8J Moderate Increased risk of ventricular arrhythmias by the combination of Bendroflumethiazide and Thioridazine. Schizophrenia [6A20] [34]
Aripiprazole DM3NUMH Moderate Additive hypotensive effects by the combination of Bendroflumethiazide and Aripiprazole. Schizophrenia [6A20] [24]
Iloperidone DM6AUFY Moderate Increased risk of ventricular arrhythmias by the combination of Bendroflumethiazide and Iloperidone. Schizophrenia [6A20] [34]
Paliperidone DM7NPJS Moderate Increased risk of ventricular arrhythmias by the combination of Bendroflumethiazide and Paliperidone. Schizophrenia [6A20] [34]
Haloperidol DM96SE0 Moderate Increased risk of ventricular arrhythmias by the combination of Bendroflumethiazide and Haloperidol. Schizophrenia [6A20] [34]
Perphenazine DMA4MRX Moderate Increased risk of ventricular arrhythmias by the combination of Bendroflumethiazide and Perphenazine. Schizophrenia [6A20] [34]
Molindone DMAH70G Moderate Additive hypotensive effects by the combination of Bendroflumethiazide and Molindone. Schizophrenia [6A20] [24]
Chlorpromazine DMBGZI3 Moderate Increased risk of ventricular arrhythmias by the combination of Bendroflumethiazide and Chlorpromazine. Schizophrenia [6A20] [34]
Thiothixene DMDINC4 Moderate Additive hypotensive effects by the combination of Bendroflumethiazide and Thiothixene. Schizophrenia [6A20] [24]
Risperidone DMN6DXL Moderate Increased risk of ventricular arrhythmias by the combination of Bendroflumethiazide and Risperidone. Schizophrenia [6A20] [34]
Amisulpride DMSJVAM Moderate Increased risk of ventricular arrhythmias by the combination of Bendroflumethiazide and Amisulpride. Schizophrenia [6A20] [34]
Asenapine DMSQZE2 Moderate Additive hypotensive effects by the combination of Bendroflumethiazide and Asenapine. Schizophrenia [6A20] [24]
Pimozide DMW83TP Major Increased risk of ventricular arrhythmias by the combination of Bendroflumethiazide and Pimozide. Schizophrenia [6A20] [38]
Atropine DMEN6X7 Minor Altered absorption of Bendroflumethiazide due to GI dynamics variation caused by Atropine. Unspecific substance harmful effect [NE6Z] [20]
Amiodarone DMUTEX3 Major Increased risk of ventricular arrhythmias by the combination of Bendroflumethiazide and Amiodarone. Ventricular tachyarrhythmia [BC71] [39]
⏷ Show the Full List of 105 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7122).
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 077833.
3 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4 BDDCS applied to over 900 drugs
5 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
6 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
9 The renal thiazide-sensitive Na-Cl cotransporter as mediator of the aldosterone-escape phenomenon. J Clin Invest. 2001 Jul;108(2):215-22.
10 Nongenomic effect of aldosterone on ion transport pathways of red blood cells. Cell Physiol Biochem. 2008;22(1-4):269-78.
11 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
12 Update of diuretics in the treatment of hypertension. Am J Ther. 2007 Mar-Apr;14(2):154-60.
13 Nerve Terminal GABAA Receptors Activate Ca2+/Calmodulin-dependent Signaling to Inhibit Voltage-gated Ca2+ Influx and Glutamate Release. J Biol Chem. 2009 Mar 27;284(13):8726-37.
14 Na-K-Cl cotransport regulates intracellular volume and monolayer permeability of trabecular meshwork cells. Am J Physiol. 1995 Apr;268(4 Pt 1):C1067-74.
15 Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs. Clin Pharmacol Ther. 2007 Sep;82(3):300-9.
16 Function and regulation of epithelial sodium transporters in the kidney of a salt-sensitive hypertensive rat model. J Hypertens. 2007 May;25(5):1065-72.
17 The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Mol Cell Endocrinol. 2004 Mar 31;217(1-2):45-52.
18 Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61. [PMID: 6701709]
19 Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA "Nadolol in combination with indapamide and xipamide in resistant hypertensives." Eur J Clin Pharmacol 28 (1985): 29-33. [PMID: 3987783]
20 Beermann B, Groschinsky-Grind M "Enhancement of the gastrointestinal absorption of hydrochlorothiazide by propantheline." Eur J Clin Pharmacol 13 (1978): 385-7. [PMID: 668798]
21 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
22 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
23 FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs).".
24 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
25 Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
26 Product Information. Savella (milnacipran). Forest Pharmaceuticals, St. Louis, MO.
27 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
28 Yassa R, Nastase C, Camille Y, Henderson M, Belzile L, Beland F "Carbamazepine, diuretics, and hyponatremia: a possible interaction." J Clin Psychiatry 48 (1987): 281-3. [PMID: 3597330]
29 Product Information. Aptiom (eslicarbazepine). Sunovion Pharmaceuticals Inc, Marlborough, MA.
30 Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57. [PMID: 10668858]
31 Burnakis TG, Mioduch HJ "Combined therapy with captopril and potassium supplementation: a potential for hyperkalemia." Arch Intern Med 144 (1984): 2371-2. [PMID: 6391404]
32 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
33 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
34 Cerner Multum, Inc. "Australian Product Information.".
35 Canadian Pharmacists Association.
36 Cohen J "Long-term efficacy and safety of terazosin alone and in combination with other antihypertensive agents." Am Heart J 122 (1991): 919-25. [PMID: 1678923]
37 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
38 Product Information. Orap Tablets (pimozide). Gate Pharmaceuticals, Sellersville, PA.
39 Antonelli D, Atar S, Freedberg NA, Rosenfeld T "Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions." Isr Med Assoc J 7 (2005): 163-5. [PMID: 15792261]